Rs 150 per Covaxin dose to Centre not sustainable in long run: Bharat Biotech

Fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among few others contribute to higher pricing of Covaxin, Bharat Biotech said justifying the higher price when compared to other COVID-19 vaccines available for the private sector in India.

Original source: https://health.economictimes.indiatimes.com/news/pharma/83539719?utm_source=RSS&utm_medium=ETRSS

Related Posts